Articles

Find an Article

Filter articles

Applied Filters

Showing 51 to 60 of 136 results

Life Technologies v Promega: the long tentacles of infringement

US12-10-2016Sandra Kuzmich and Russell Garman

Global companies are watching a pending life sciences patent case at the US Supreme Court because of its potential impact both within and outside US borders, as Sandra Kuzmich and Russell Garman of Frommer Lawrence & Haug explain.

Francis Crick Institute: a new centre of excellence

UK11-10-2016

In September 2016, the Francis Crick Institute opened the doors to its multimillion-pound new home in London. With a wide range of research being undertaken, LSIPR examines the role of IP and the associated challenges for the organisation.

Event preview: Life Sciences Patents Network Europe 2016

EU07-10-2016

On December 7, LSIPR will be hosting the Life Sciences Patents Network Europe 2016 at the Bloomsbury Hotel in London. Here we preview the main talking points.

LSIPR 50 2016: Robert Langer

US05-10-2016

Robert Langer was selected in the LSIPR 50 2016 publication for his influence on the life sciences industry. Langer was featured in the business and innovation section, as LSIPR reports.

Preview: Life Sciences IP Summit 2016

EU16-09-2016Sarah Porch

Ahead of the Life Sciences IP Summit 2016 from October 20 to 21 at the Hilton London Paddington Hotel, Sarah Porch of C5 previews the main talking points, including Brexit and the UPC.

Drug price regulation in Brazil: Roche faces IP rights abuse claims

Brazil02-08-2016Anderson Ribeiro and Ricardo Campello

The Brazilian Federal Prosecutor’s Office has taken court action against Roche for allegedly abusing IP rights in its sales of Herceptin to state governments. Anderson Ribeiro and Ricardo Campello of Provedel Advogados analyse the case.

Under surveillance: generic and biosimilar MAs

EU26-07-2016Ruth Franken

In order to be well prepared before a generic or biosimilar marketing authorisation is approved, drugs companies in the EU may consider monitoring pending applications, says Ruth Franken of Hogan Lovells.

From the EU to Australia: latest SPC developments

Australia, EU07-07-2016Gareth Morgan

Legislative developments surrounding supplementary protection certificates in the EU are moving fast, and may be catching on as far afield as Australia. Gareth Morgan of Olswang explains more.

Brexit and IP: business as usual, for now

EU, UK07-07-2016Claire Phipps-Jones

Following the UK’s vote to leave the EU, it is business as usual for life sciences companies working with intellectual property, at least for now, says Claire Phipps-Jones of Bristows.

Breathing life into patents

US07-06-2016MaryAnne Armstrong

Applicants wishing to extend their patents’ term of protection do not have to necessarily match up the wording of the claims and the label of the relevant drug for there to be infringement by an ANDA, as MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch reports.

Showing 51 to 60 of 136 results

LSIPR